読み込み中
NASDAQHealthcareMedical - Devices
最新データ
$6.77
+$0.14 · +2.11%
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
前日終値
$6.77
+$0.14 · +2.11%
日中の時刻はETです。市場データは遅延する場合があります。
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
日中レンジ
現在 $6.77
52週レンジ
現在 $6.77
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
26
割高
センチメント
60
まちまち
リスク
42
やや高いリスク
モメンタム
70
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
日中レンジ
現在 $6.77
52週レンジ
現在 $6.77
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 191.3万 USD | 270.3万 USD | 273.48万 USD | 320.07万 USD | 583.05万 USD |
| 売上原価 | 223万 USD | 143.7万 USD | 185.8万 USD | 290.23万 USD | 392.54万 USD |
| 粗利益 | −31.7万 USD | 126.6万 USD | 87.68万 USD | 29.84万 USD | 190.52万 USD |
| 研究開発 | 6912万 USD | 5145.1万 USD | 3102.16万 USD | 1759.01万 USD | 999.49万 USD |
| 販売・一般管理 | 2445.7万 USD | — | 1704.57万 USD | 1521.34万 USD | 913.54万 USD |
| 営業費用 | 9357.7万 USD | 7963.8万 USD | 4901.68万 USD | 3141.27万 USD | 1876.57万 USD |
| 受取利息 | 70.9万 USD | — | 42.81万 USD | 21.04万 USD | 6.86万 USD |
| 支払利息 | 7.3万 USD | 8.2万 USD | 6.71万 USD | 64.87万 USD | 103.42万 USD |
| 減価償却費と償却費 | 166.1万 USD | 150.7万 USD | 115.77万 USD | 77.41万 USD | 64.01万 USD |
| 営業利益 | −9389.4万 USD | −7837.2万 USD | −4814万 USD | −3111.43万 USD | −1686.06万 USD |
| 純利益 | −9414.4万 USD | −7629.1万 USD | −4602.18万 USD | −3056.38万 USD | −1717.11万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM1346.47万0.02%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF766.33万0.01%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO404.54万0.02%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA284.19万0.01%218.24億 USD0.03%$32.79+0.40%
State Street SPDR S&P Health Care Equipment ETFXHE199.51万1.15%1.74億 USD0.35%$89.47+1.51%
iShares Micro-Cap ETFIWC160.82万0.12%13.17億 USD0.60%$183+0.11%
Fidelity Enhanced Small Cap ETFFESM102.52万0.02%64.1億 USD0.28%$45.46+0.46%
iShares Core S&P Total U.S. Stock Market ETFITOT74.7万0.00%980.88億 USD0.03%$169.66+0.64%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAState Street SPDR S&P Health Care Equipment ETFXHEiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMiShares Core S&P Total U.S. Stock Market ETFITOTAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
